Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents

Simple item page
dc.article.number1372193
dc.article.number1372193
dc.catalogadoraba
dc.contributor.authorRivera Pérez, Daniela
dc.contributor.authorMéndez Vejar, Constanza Soledad
dc.contributor.authorDiethelm Varela, Benjamín Manuel
dc.contributor.authorMelo González, Felipe Andrés
dc.contributor.authorVázquez Hernández, Yaneisi
dc.contributor.authorMeng, Xing
dc.contributor.authorXin, Qianqian
dc.contributor.authorFasce, Rodrigo A.
dc.contributor.authorFernández, Jorge
dc.contributor.authorMora, Judith
dc.contributor.authorRamírez, Eugenio
dc.contributor.authorAcevedo, Mónica L.
dc.contributor.authorValiente Echeverria, Fernando
dc.contributor.authorSoto Rifo, Ricardo
dc.contributor.authorGrifoni, Alba
dc.contributor.authorWeiskopf, Daniela
dc.contributor.authorSette, Alessandro
dc.contributor.authorAstudillo Paredes, Patricio Andrés
dc.contributor.authorLe Corre Pérez, Monique Nicole
dc.contributor.authorAbarca Villaseca, Katia
dc.contributor.authorPerret Pérez, Cecilia
dc.contributor.authorGonzález Muñoz, Pablo Alberto
dc.contributor.authorSoto Ramírez, Jorge Andrés
dc.contributor.authorBueno Ramírez, Susan
dc.contributor.authorKalergis, Alexis M.
dc.date.accessioned2024-06-14T20:48:32Z
dc.date.available2024-06-14T20:48:32Z
dc.date.issued2024
dc.description.abstractBackground: Vaccine effectiveness against SARS-CoV-2 infection has been somewhat limited due to the widespread dissemination of the Omicron variant, its subvariants, and the immune response dynamics of the naturally infected with the virus. Methods: Twelve subjects between 3-17 years old (yo), vaccinated with two doses of CoronaVac®, were followed and diagnosed as breakthrough cases starting 14 days after receiving the second dose. Total IgGs against different SARS-CoV-2 proteins and the neutralizing capacity of these antibodies after infection were measured in plasma. The activation of CD4+ and CD8+ T cells was evaluated in peripheral blood mononuclear cells stimulated with peptides derived from the proteins from the wild-type (WT) virus and Omicron subvariants by flow cytometry, as well as different cytokines secretion by a Multiplex assay. Results: 2 to 8 weeks post-infection, compared to 4 weeks after 2nd dose of vaccine, there was a 146.5-fold increase in neutralizing antibody titers against Omicron and a 38.7-fold increase against WT SARS-CoV-2. Subjects showed an increase in total IgG levels against the S1, N, M, and NSP8 proteins of the WT virus. Activated CD4+ T cells showed a significant increase in response to the BA.2 subvariant (p<0.001). Finally, the secretion of IL-2 and IFN-γ cytokines showed a discreet decrease trend after infection in some subjects. Conclusion: SARS-CoV-2 infection in the pediatric population vaccinated with an inactivated SARS-CoV-2 vaccine produced an increase in neutralizing antibodies against Omicron and increased specific IgG antibodies for different SARS-CoV-2 proteins. CD4+ T cell activation was also increased, suggesting a conserved cellular response against the Omicron subvariants, whereas Th1-type cytokine secretion tended to decrease. Clinical Trial Registration: clinicaltrials.gov #NCT04992260
dc.description.funderNational Agency for Research and Development
dc.description.funderANID
dc.description.funderNational Institutes of Health
dc.description.funderNational Institute of Allergy and Infectious Diseases
dc.description.funderSinovac Biotech
dc.description.funderFondo Nacional de Desarrollo Científico y Tecnológico
dc.description.funderFondo Nacional de Desarrollo Científico y Tecnológico
dc.description.funderDepartment of Health and Human Services
dc.description.funderDepartment of Health and Human Services
dc.description.funderANID-Millennium
dc.description.funderANID/FONDECYT
dc.description.funderANID-Millennium Science Initiative Program
dc.fechaingreso.objetodigital2024-06-14
dc.fuente.origenSCOPUS
dc.identifier.doi10.3389/fimmu.2024.1372193
dc.identifier.issn1664-3224
dc.identifier.scopusidSCOPUS_ID:85194747874
dc.identifier.urihttps://doi.org/10.3389/fimmu.2024.1372193
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/86782
dc.identifier.wosidWOS:001233705500001
dc.information.autorucFacultad de Ciencias Biológicas; Rivera Pérez, Daniela; S/I; 1175592
dc.information.autorucEscuela de Medicina; Méndez Vejar, Constanza Soledad; 0000-0002-1509-4471; 1036010
dc.information.autorucFacultad de Ciencias Biológicas; Diethelm Varela, Benjamín Manuel; 0000-0002-5465-6924; 217234
dc.information.autorucFacultad de Ciencias Biológicas; Melo González, Felipe Andrés; 0000-0002-3711-2407; 149763
dc.information.autorucFacultad de Ciencias Biológicas; Vázquez Hernández, Yaneisi; S/I; 1025308
dc.information.autorucEscuela de Medicina; Astudillo Paredes, Patricio Andrés; S/I; 179203
dc.information.autorucEscuela de Medicina; Le Corre Pérez, Monique Nicole; 0000-0002-9361-4049; 6737
dc.information.autorucEscuela de Medicina; Abarca Villaseca, Katia; 0000-0003-0404-3887; 70281
dc.information.autorucEscuela de Medicina; Perret Pérez, Cecilia; 0000-0002-1535-1204; 80387
dc.information.autorucFacultad de Ciencias Biológicas; González Muñoz, Pablo Alberto; 0000-0001-7709-6870; 15616
dc.information.autorucFacultad de Ciencias Biológicas; Soto Ramírez, Jorge Andrés; 0000-0003-0335-9759; 237269
dc.information.autorucFacultad de Ciencias Biológicas; Bueno Ramírez, Susan; 0000-0002-7551-8088; 113541
dc.language.isoen
dc.nota.accesocontenido completo
dc.pagina.final13
dc.pagina.inicio1
dc.publisherFrontiers Media SA
dc.revistaFrontiers in Immunology
dc.rightsacceso abierto
dc.rights.licenseATTRIBUTION 4.0 INTERNATIONAL
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectBreakthrough cases
dc.subjectCoronaVac®
dc.subjectInactivated SARS-CoV-2 vaccine
dc.subjectOmicron variant
dc.subjectPediatric
dc.subjectPhase 3 clinical trial
dc.subjectSARS-CoV-2
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleImmune responses during COVID-19 breakthrough cases in vaccinated children and adolescents
dc.typeartículo
dc.volumen15
sipa.codpersvinculados1175592
sipa.codpersvinculados1036010
sipa.codpersvinculados217234
sipa.codpersvinculados149763
sipa.codpersvinculados1025308
sipa.codpersvinculados179203
sipa.codpersvinculados6737
sipa.codpersvinculados70281
sipa.codpersvinculados80387
sipa.codpersvinculados15616
sipa.codpersvinculados237269
sipa.codpersvinculados113541
sipa.trazabilidadSCOPUS;2024-06-09
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fimmu-15-1372193 (1).pdf
Size:
2.99 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas